Law360, New York (June 13, 2012, 1:58 PM ET) -- Health plans and other third-party payors accusing Pfizer Inc. of fraudulently promoting epilepsy drug Neurontin to treat bipolar disorder on Monday told the First Circuit their claims had been improperly dismissed from the multidistrict litigation over Pfizer’s alleged off-label marketing.
The MDL against Pfizer consolidated cases filed by consumers and health insurance companies around the country accusing the drug company of pushing off-label uses of Neurontin that studies showed were not effective.
The appellants said U.S. District Judge Patti Saris wrongly dismissed them from the MDL...
Payors Urge 1st Circ. To Revive Pfizer Neurontin MDL Claims
To view the full article, take a free trial now.
